AbbVie posts results for Japan CLL/SLL study; also files new Phase 3 NSCLC trial vs pembrolizumab

The week's most notable item was a results posting for a completed CLL/SLL study, alongside a newly registered Phase 3 lung cancer trial and routine updates to two other studies.

• AbbVie posted results for NCT05105841, a Phase 2 study testing venetoclax in combination with obinutuzumab or with ibrutinib in Japanese participants with previously untreated CLL/Small Lymphocytic Lymphoma (SLL)¹. The study is listed as completed, with approximately 20 adult participants enrolled in the study at approximately 20 sites in Japan¹, and results were first posted 2026-10-21.
• AbbVie registered a new Phase 3 trial (NCT07756645) testing ABBV-1480 with platinum based chemotherapy against standard of care pembrolizumab with platinum based chemotherapy² for first line treatment of adult participants with locally advanced (Stage IIIB/C) or metastatic (Stage IV) sqNSCLC, with up to approximately 940 participants enrolled in approximately 250 sites globally². Status is listed as recruiting, with an estimated start of 2026-09-22.
• The Phase 2/3 "LIVIGNO-4" study (NCT06236438), testing livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer³, had its record last updated 2026-10-19. The study plans to enroll approximately 840 adult participants across 200 sites worldwide³, though current enrollment is listed as 167 participants (actual) with status active, not recruiting.
• AbbVie's Phase 3 study of NOA HYDRATION (NCT07880756), an investigational device being developed for improvement of facial skin quality including attributes such as skin smoothness⁴, remains listed as recruiting. The study has an estimated enrollment of approximately 150 adult participants seeking improvement in skin quality including attributes such as skin smoothness at approximately 7 sites in China⁴.